It is the opinion of this expert panel that better utilization of biosimilar anti-TNF-α agents is key for accelerating and optimizing early, high efficacy treatment in IBD, particularly for patients with moderate-to-severe CD. The gene discussed is TNF; the disease is inflammatory bowel disease.